Tiankang Bio released its 2026 interim report, showing total operating revenue of 8.325 billion yuan, down 5.89% year on year, while net profit attributable to the parent company was a loss of 441 million yuan, swinging from profit to loss with a decline of 230.50%. Net cash inflow from operating activities was 1.496 billion yuan, down 7.60% year on year. The company's asset-liability ratio was 55.56%, gross margin was 1.43%, return on equity was negative 6.96%, and diluted earnings per share was negative 0.32 yuan.
Xinjiang Tecon Animal Husbandry Bio-Technology Co LtdNet loss of 441 million yuan, swinging from profit to loss with a 230.50% decline.